Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International Inc.

Cresco Labs ( ($TSE:CL) ) has shared an update. Cresco Labs has been conditionally awarded a vertically integrated license under the Texas Compassi...

Cresco Labs Secures Vertically Integrated Medical Cannabis License in Texas

The latest announcement is out from Creightons ( ($GB:CRL) ). Creightons plc reported that non-executive director and PDMR Paul Watts carried out a...

Creightons Director’s Matched Share Deal Leaves Stake Unchanged

In a report released on March 13, Rob Mann from RBC Capital maintained a Buy rating on Cardinal Energy, with a price target of C$11.00. The company...

RBC Capital Reaffirms Their Buy Rating on Cardinal Energy (CJ)

In a report released on March 11, Niccolo Guido Storer from Kepler Capital maintained a Buy rating on Carel Industries SpA, with a price target of ...

Kepler Capital  Keeps Their Buy Rating on Carel Industries SpA (CIG)

Cardinal Energy ( ($TSE:CJ) ) has provided an update. Cardinal Energy reported record fourth-quarter 2025 production of 23,514 boe/d, driven by the...

Cardinal Energy Lifts Output on Reford SAGD as Lower Prices Squeeze Cash Flow

Creightons ( ($GB:CRL) ) has provided an announcement. Creightons plc reported its latest six‑monthly block admission return for its employee share...

Creightons Keeps Block Admission Balance Unchanged as No Options Exercised

The latest update is out from Cardinal Energy ( ($TSE:CJ) ). Cardinal Energy Ltd. has declared a monthly cash dividend of $0.06 per common share fo...

Cardinal Energy Declares March Cash Dividend

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aligos Therapeutics (ALGS – Research Report) and Cre...

Current Quarter	$2.01	Next Quarter	$2.81
Current Year	$10.94	Next Year	$11.85
QoQ Growth	+39.8%	YoY Growth	+8.3%
3Y EPS CAGR	-70.5%	Target Price	$202.64
Consensus	Buy	Upside	+15.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRL	$175.16	+3.31%	604.43K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRL	$175.16	+3.3%	604.43K
3
4
5
6

CRL

CRL

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Charles River Laboratories International Inc. Data in Excel

Get Charles River Laboratories International Inc. Data in Excel